Robert More Biography and Net Worth

Major Shareholder of Allakos


Robert J. More serves as Independent Director of the Company. Since October 2016, Mr. More has served as Managing Director of Alta Partners, a venture capital firm. From July 2013 to May 2015, Mr. More served as Senior Advisor for the Bill & Melinda Gates Foundation and led its Global Health Venture Initiative. He served as a General Partner of venture capital firms Frazier Healthcare Ventures and Domain Associates from September 2008 to June 2013 and from June 1996 to July 2008, respectively. Mr. More currently serves on the board of directors of Sienna Biopharmaceuticals, Inc., a public pharmaceutical company. He also currently serves on the board of directors of the following private companies: Affinivax, Inc., a biotechnology company, eGenesis, a biotechnology company, Qihan Biotech, a biotechnology company, Sirenas, LLC, a biotechnology company, Tyra Biosciences, Inc., a biotechnology company, and as an advisor on Liquiglide, Inc. a biotechnology company. Mr. More previously served on the board of directors of the following public companies: Achaogen, Inc., a biopharmaceutical company, Carticept Medical, Inc., a medical device company, Cartiva, a medical device company, Neothetics Inc., a pharmaceutical company, Glaukos Corporation, a medical technology company, and IntraLase Corp., a medical device company acquired by Advanced Medical Optics in 2007. He also previously served on the board of directors of the following life sciences companies: ESP Pharma, Inc., Proxima Therapeutics, Inc., NovaCardia, Inc., Esprit Pharma, Inc. and Oceana Therapeutics, Inc. Mr. More was a founding member of the board of directors of the Kauffman Fellows Program and previously served on the board of directors of One Revolution and The Foundation for Innovative New Diagnostics (FIND). Mr. More currently serves on one of the governing boards of the Biotechnology Innovation Organization (BIO). He received his B.S. in Biology from Middlebury College and an M.B.A. from the Darden School of Business Administration at the Universi

What is Robert J. More's net worth?

The estimated net worth of Robert J. More is at least $73,531.14 as of June 17th, 2021. Mr. More owns 69,369 shares of Allakos stock worth more than $73,531 as of April 18th. This net worth approximation does not reflect any other investments that Mr. More may own. Learn More about Robert J. More's net worth.

How do I contact Robert J. More?

The corporate mailing address for Mr. More and other Allakos executives is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. Allakos can also be reached via phone at (650) 597-5002 and via email at [email protected]. Learn More on Robert J. More's contact information.

Has Robert J. More been buying or selling shares of Allakos?

Robert J. More has not been actively trading shares of Allakos during the last quarter. Learn More on Robert J. More's trading history.

Who are Allakos' active insiders?

Allakos' insider roster includes Robert Alexander (CEO), Peter Hudson (Major Shareholder), Steven James (Director), Daniel Janney (Director), Robert More (Major Shareholder), Henrik Rassmussen (Insider), and Adam Tomasi (COO). Learn More on Allakos' active insiders.

Robert J. More Insider Trading History at Allakos

See Full Table

Robert J. More Buying and Selling Activity at Allakos

This chart shows Robert J. More's buying and selling at Allakos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Allakos Company Overview

Allakos logo
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $1.06
Low: $1.03
High: $1.08

50 Day Range

MA: $1.30
Low: $1.05
High: $1.64

2 Week Range

Now: $1.06
Low: $1.00
High: $5.64

Volume

336,696 shs

Average Volume

1,328,430 shs

Market Capitalization

$93.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82